We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Interleukin‐31 and interleukin‐31 receptor: New therapeutic targets for atopic dermatitis.
- Authors
Nakashima, Chisa; Otsuka, Atsushi; Kabashima, Kenji
- Abstract
Abstract: Atopic dermatitis (AD) is characterized by chronic, eczematous, severe pruritic skin lesions caused by skin barrier dysfunction and T helper (Th)2 cell‐mediated immunity. Interleukin (IL)‐31 is a potent pruritogenic cytokine primarily produced by Th2 cells. Both IL‐31 transgenic mice and wild‐type mice treated with IL‐31 exhibit AD‐like skin lesions and scratching behaviour. IL‐31 receptor α‐chain (IL‐31RA) is also expressed in peripheral nerves and epidermal keratinocytes, and the roles of IL‐31 on pruritus and skin barrier have been investigated. Recently, an anti–IL‐31 receptor antibody was shown to significantly improve pruritus in AD patients. This review focuses on IL‐31 and IL‐31RA in AD.
- Subjects
INTERLEUKINS; INTERLEUKIN receptors; ATOPIC dermatitis; SKIN inflammation diagnosis; KERATINOCYTES
- Publication
Experimental Dermatology, 2018, Vol 27, Issue 4, p327
- ISSN
0906-6705
- Publication type
Article
- DOI
10.1111/exd.13533